Breaking
Friday, June 19, 2026

Drug Approvals

🇺🇸 FDA Page 7

FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page

Track global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.

Showing 73–84 of 665 articles

High impact NewsJun 5, 2026

Alabama Board of Medical Examiners Issues Warning on Non-FDA-Approved Peptides: What Pharma Teams Need to Know

FDA · 4 min

Dr. Sarah Mitchell
High impact NewsJun 5, 2026

Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

FDA · IgA Nephropathy · 4 min

Dr. Sarah Mitchell
Critical impact NewsJun 5, 2026

Aurobindo Pharma OAI Classification: Implications for Drug Approvals

FDA · 5 min

Dr. Sarah Mitchell
High impact NewsJun 5, 2026

Lee, Tuberville Introduce Protections for Homeopathic Medicine with FDA Approval Framework

FDA · 4 min

Dr. Sarah Mitchell
High impact NewsJun 5, 2026

Daraxonrasib Doubles Survival in Pancreatic Cancer: What Pharma Teams Need to Know

pancreatic cancer · 4 min

Dr. Sarah Mitchell
Critical impact NewsJun 5, 2026

FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis

FDA · COVID-19 · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

FDA Priority Review Voucher Program: Will Makary's Initiative Survive?

FDA · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors

oncology · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

Grail’s Galleri Trial Missed Its Primary Endpoint: What BD Teams and Investors Need to Know

cancer · 5 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

Top 10 Pharmaceutical Stocks to Buy for June 2026: A B2B Analysis

EMA · 7 min

Dr. Sarah Mitchell
High impact AnalysisJun 5, 2026

FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies

FDA · 6 min

Dr. Sarah Mitchell
Critical impact AnalysisJun 5, 2026

STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors

Supreme Court · 6 min

Dr. Sarah Mitchell